Please ensure Javascript is enabled for purposes of website accessibility

Why Vir Biotechnology Stock Is Dropping Today

By Prosper Junior Bakiny - Mar 3, 2021 at 11:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company provided a discouraging regulatory update.

What happened?

Shares of Vir Biotechnology (VIR -4.06%) are plunging on Wednesday following the company's release of an update regarding one of its leading pipeline candidates. At 12:28 p.m. EST the drugmaker's stock was down by 33% after falling by as much as 35.3% earlier in the day. 

So what

Vir Biotechnology, in collaboration with GlaxoSmithKline, is developing VIR-7831, a potential antibody treatment for COVID-19. It is undergoing a phase 3 clinical trial as part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program, an initiative spearheaded by the U.S. National Institutes of Health (NIH). However, a sensitivity analysis of the data from the trial by the independent Data and Safety Monitoring Board (DSMB) raised concerns that VIR-7831 may not be a very effective treatment. As a result, the DSMB recommended that the VIR-7831 arm of the ACTIVE-3 trial be closed to enrollment, despite the medicine's meeting criteria to move on to the next phase. Note that the study did not raise safety concerns about VIR-7831.

Man holding his forehead in panic with a downward-bound graph in the background.

Image source: Getty Images.

Now what

Vir Biotechnology's shareholders had very high hopes for VIR-7831, and with good reason. The biotech company currently has no products on the market, and this experimental medicine is currently one of its most advanced pipeline candidates. Despite the growing availability of COVID-19 vaccines, there will likely be a need for effective therapies for the disease in the future. But given today's developments, the future of VIR-7831 is now uncertain, which explains why investors are choosing to sell off Vir Biotechnology's stock. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$24.84 (-4.06%) $-1.05
GSK Stock Quote
GSK
GSK
$43.69 (2.20%) $0.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.